The U.S. Food and Drug Administration (FDA) today approved Hemgenix-Next, an adeno-associated virus (AAV) vector-based gene therapy for the treatment of adults with Hemophilia B.
A One-Time Treatment
Unlike current standard-of-care treatments that require regular intravenous infusions of Factor IX, this new therapy is designed as a one-time infusion. It delivers a functional copy of the Factor IX gene to the liver cells.
Clinical Trial Efficacy
In the pivotal HOPE-B trial, patients demonstrated:
- A 64% reduction in annualized bleeding rate (ABR).
- Stable Factor IX expression levels for over 24 months post-infusion.
- No serious adverse events related to the therapy.
Impact on the Market
This approval is expected to shift the paradigm of Hemophilia care, moving from chronic management to potential functional cures. Analysts predict the gene therapy market will grow by 20% annually through 2030.
